Edition:
United States

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

2.76USD
24 Mar 2017
Change (% chg)

$-0.01 (-0.36%)
Prev Close
$2.77
Open
$2.79
Day's High
$2.82
Day's Low
$2.74
Volume
184,628
Avg. Vol
192,636
52-wk High
$2.89
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

Antares Pharma Q4 loss per share $0.03
Tuesday, 14 Mar 2017 07:00am EDT 

Antares Pharma Inc : Antares pharma reports fourth quarter and full year 2016 operating and financial results . Q4 loss per share $0.03 . Q4 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S .Revenue was $14.2 million for three months ended december 31, 2016 compared to $11.8 million for comparable period in 2015.  Full Article

Antares Pharma reported a preliminary net loss per share of $0.03
Monday, 6 Mar 2017 08:25am EST 

Antares Pharma Inc : Antares Pharma Inc - company reported preliminary total revenue of $14.2 million and $52.2 million for quarter and year ended december 31, 2016, respectively . Antares Pharma Inc- reported a preliminary net loss per share of $0.03 for quarter ended December 31, 2016 . Q4 earnings per share view $-0.04, revenue view $11.2 million -- Thomson Reuters I/B/E/S . Molson Coors Brewing Co - company reported a preliminary net loss per share of $0.16 for year ended December 31, 2016 .FY2016 earnings per share view $-0.17, revenue view $49.3 million -- Thomson Reuters I/B/E/S.  Full Article

Antares Pharma announces FDA acceptance of new drug application for Quickshot testosterone
Monday, 27 Feb 2017 07:00am EST 

Antares Pharma Inc :Antares Pharma announces FDA acceptance of new drug application for Quickshot testosterone.  Full Article

Antares Pharma appoints Fred Powell as CFO, senior VP
Monday, 31 Oct 2016 09:00am EDT 

Antares Pharma Inc : Antares Pharma Inc says most recently, Powell served as vice president and chief financial officer for Celator Pharmaceuticals .Antares Pharma appoints Fred M. Powell, senior vice president and chief financial officer.  Full Article

Antares Pharma cfo to step down
Thursday, 11 Aug 2016 07:11am EDT 

Antares Pharma Inc : On august 5, 2016, co received written notice of resignation from james fickenscher, co's senior vice president and cfo . Company has initiated a search for a new chief financial officer - sec filing . Keith muckenhirn to assume roles of interim cfo, principal accounting officer while co completes search process for permanent cfo .Fickenscher's resignation will become effective september 4, 2016.  Full Article

Antares Pharma Q2 loss per share $0.04
Tuesday, 9 Aug 2016 07:00am EDT 

Antares Pharma Inc : Antares pharma reports second quarter 2016 operating and financial results . Q2 revenue $24.5 million . Q2 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S .Q2 revenue view $11 million -- Thomson Reuters I/B/E/S.  Full Article

Antares Pharma posts Q1 loss per share of $0.05
Monday, 9 May 2016 07:00am EDT 

Antares Pharma Inc : Antares Pharma reports first quarter 2016 operating and financial results . Q1 revenue $12.3 million versus I/B/E/S view $11.1 million . Q1 loss per share $0.05 .Q1 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.  Full Article

Antares Pharma Inc announces CEO transition
Tuesday, 26 Jan 2016 08:00am EST 

Antares Pharma Inc:Board of Directors has appointed Robert Apple to the position of President and Chief Executive Officer.Apple succeeds Eamonn P. Hobbs.Hobbs also resigned as a member of the Board of Directors.  Full Article

Antares Pharma announces FDA Approval of Sumatriptan Injection USP
Monday, 14 Dec 2015 09:00am EST 

Antares Pharma Inc:Announced that the U.S. FDA has approved its Abbreviated New Drug Application (ANDA) for 4 mg/0.5 mL and 6 mg/0.5 mL Sumatriptan Injection USP in adults for the acute treatment of migraine and cluster headache when a clear diagnosis has been established.  Full Article

Antares Pharma Inc announces closing of public offering of common stock
Monday, 11 May 2015 04:05pm EDT 

Antares Pharma, Inc:Closes underwritten public offering of 23,000,000 shares.Says this includes 3,000,000 shares pursuant to underwriters' exercise of their option in full, at purchase price to public of $2.00 per share.Net proceeds is $43.2 mln.Piper Jaffray & Co. is acting as sole book-running manager for the offering.Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as the co-managers of the offering.  Full Article

More From Around the Web

BRIEF-Antares Pharma Q4 loss per share $0.03

* Antares pharma reports fourth quarter and full year 2016 operating and financial results

No consensus analysis data available.